Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Ichthyosis vulgaris Indication Strategy Report 2026: FLG, Trials and Deals
23 July 2026
2026 Ichthyosis vulgaris strategy: epidemiology, FLG biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Junctional epidermolysis bullosa Indication Strategy Report 2026: LAMB3, Trials and Deals
23 July 2026
2026 Junctional epidermolysis bullosa strategy: epidemiology, LAMB3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Dystrophic epidermolysis bullosa Indication Strategy Report 2026: COL7A1, Trials and Deals
23 July 2026
2026 Dystrophic epidermolysis bullosa strategy: epidemiology, COL7A1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Epidermolysis bullosa Indication Strategy Report 2026: COL7A1, Trials and Deals
23 July 2026
2026 Epidermolysis bullosa strategy: epidemiology, COL7A1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Sweet syndrome Indication Strategy Report 2026: IL-1β, Trials and Deals
23 July 2026
2026 Sweet syndrome strategy: epidemiology, IL-1β biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Pyoderma gangrenosum Indication Strategy Report 2026: IL-1β, Trials and Deals
23 July 2026
2026 Pyoderma gangrenosum strategy: epidemiology, IL-1β biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Palmoplantar pustulosis Indication Strategy Report 2026: IL-36R, Trials and Deals
23 July 2026
2026 Palmoplantar pustulosis strategy: epidemiology, IL-36R biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Generalized pustular psoriasis Indication Strategy Report 2026: IL-36R, Trials and Deals
23 July 2026
2026 Generalized pustular psoriasis strategy: epidemiology, IL-36R biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pityriasis rubra pilaris Indication Strategy Report 2026: IL-17A, Trials and Deals
23 July 2026
2026 Pityriasis rubra pilaris strategy: epidemiology, IL-17A biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Lichen sclerosus Indication Strategy Report 2026: IL-4Rα, Trials and Deals
23 July 2026
2026 Lichen sclerosus strategy: epidemiology, IL-4Rα biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Lichen planus Indication Strategy Report 2026: JAK1, Trials and Deals
23 July 2026
2026 Lichen planus strategy: epidemiology, JAK1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Allergic contact dermatitis Indication Strategy Report 2026: IL-4Rα, Trials and Deals
23 July 2026
2026 Allergic contact dermatitis strategy: epidemiology, IL-4Rα biology, clinical competition, recent deals, unmet need and market attractiveness.